Email Us
Call Us
Natural killer cells recognize and kill transformed cells without prior antigen sensitization, through a balance of activating and inhibitory receptor signaling rather than through a single defined target. That mechanism gives unmodified NK cell therapy a breadth that receptor-directed approaches lack, and makes it applicable where a suitable tumor-specific antigen has not been identified.
Altogen Labs conducts preclinical evaluation of NK cell products, including expanded primary NK cells, NK cell lines, and iPSC-derived NK products, across disseminated and solid tumor models. To discuss a study design, request a quote.
What determines activity
NK killing depends on the balance of signals a target cell presents. Loss of major histocompatibility complex class I expression, a common tumor escape mechanism from T-cell recognition, removes inhibitory signaling and renders a cell more susceptible to NK killing. Stress ligand expression provides activating signal. Model selection should therefore account for the receptor-ligand profile of the tumor line rather than treating all tumor models as equivalent substrates, since two lines of the same histology can differ substantially in NK susceptibility.
Antibody-dependent cellular cytotoxicity is a second mechanism relevant to combination work, where an NK product is paired with a therapeutic antibody and killing proceeds through Fc receptor engagement. Studies addressing this require the antibody and the NK product to be evaluated alone and together, since the combination effect is the endpoint rather than the sum of the two.
Cytokine dependence
As with engineered NK products, human NK cells require cytokine support for survival and expansion in vivo, and murine cytokines do not substitute adequately. Persistence measured in a host without that support reflects the model rather than the product. Host selection, supplementation strategy, or product cytokine independence is settled at design stage and reported alongside persistence data.
Endpoints
Antitumor activity is assessed by tumor volume in solid models and by imaging in disseminated models. Persistence, trafficking, and phenotype of the transferred product are quantified by flow cytometry in blood, tumor, spleen, and marrow. Cytokine profiling characterizes the response, and immunohistochemistry establishes whether transferred cells entered the tumor mass in solid models.
Applied examples
MHC-dependent susceptibility. An NK product is evaluated against tumor lines differing in class I expression, relating antitumor activity to inhibitory ligand status rather than to histology alone.
Antibody combination. An NK product is combined with a therapeutic antibody directed at the tumor, with single agent and combination arms establishing the contribution of antibody-dependent cytotoxicity to the observed effect.
Trafficking to solid tumor. Transferred cells are quantified in tumor, blood, and spleen at defined timepoints, establishing whether limited activity in a solid model reflects poor killing or poor trafficking, which are different problems with different solutions.
Interpretive limits and service boundary
Murine hosts reproduce human NK biology incompletely, and the receptor-ligand interactions governing NK recognition are species specific. Results establish activity within the model system used, and the characteristics of that system are reported explicitly so results are not over-extended.
Altogen Labs evaluates cell products supplied by the client. Manufacture of NK cell products is not offered. All procedures are conducted under active IACUC protocols. GLP standards are applied where a study is formally designated as GLP.
Send product type, tumor indication, and mechanism of interest, or request a quote.